119 related articles for article (PubMed ID: 4076327)
1. Improved benefit/risk ratio of higher-dose metoclopramide therapy during cisplatin-induced emesis.
Saller R; Hellenbrecht D; Hellstern A; Hess H
Eur J Clin Pharmacol; 1985; 29(3):311-2. PubMed ID: 4076327
[TBL] [Abstract][Full Text] [Related]
2. Dose-response relationships of the objective and subjective antiemetic effects and of different side effects of metoclopramide against cisplatin induced emesis.
Hellenbrecht D; Saller R
Arzneimittelforschung; 1986 Dec; 36(12):1845-9. PubMed ID: 3566848
[TBL] [Abstract][Full Text] [Related]
3. [Benefit and risk of high-dose metoclopramide in comparison to high-dose haloperidol or triflupromazine in cisplatin-induced vomiting].
Saller R; Hellenbrecht D
Klin Wochenschr; 1985 May; 63(9):428-32. PubMed ID: 4039775
[TBL] [Abstract][Full Text] [Related]
4. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556
[TBL] [Abstract][Full Text] [Related]
5. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.
Lancet; 1992 Jul; 340(8811):96-9. PubMed ID: 1352024
[TBL] [Abstract][Full Text] [Related]
6. Metoclopramide. A review of antiemetic trials.
Gralla RJ
Drugs; 1983 Feb; 25 Suppl 1():63-73. PubMed ID: 6682376
[TBL] [Abstract][Full Text] [Related]
7. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
[TBL] [Abstract][Full Text] [Related]
8. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial.
Gebbia V; Testa A; Valenza R; Cannata G; Tirrito ML; Gebbia N
Cancer; 1995 Nov; 76(10):1821-8. PubMed ID: 8625054
[TBL] [Abstract][Full Text] [Related]
9. High doses of metoclopramide or droperidol in the prevention of cisplatin-induced emesis.
Saller R; Hellenbrecht D
Eur J Cancer Clin Oncol; 1986 Oct; 22(10):1199-203. PubMed ID: 3545851
[TBL] [Abstract][Full Text] [Related]
10. Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial.
Shinkai T; Saijo N; Eguchi K; Sasaki Y; Tamura T; Fujiwara Y; Mae M; Fukuda M; Ohe Y; Sasaki S
Jpn J Clin Oncol; 1989 Mar; 19(1):40-4. PubMed ID: 2921817
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind comparison of the antiemetic effect of metoclopramide and lorazepam with or without dexamethasone in patients receiving high-dose cisplatin.
Stephens SH; Silvey VL; Wheeler RH
Cancer; 1990 Aug; 66(3):443-6. PubMed ID: 2194642
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of the antiemetic action of metoclopramide against cisplatin-induced emesis by transdermal electrical nerve stimulation.
Saller R; Hellenbrecht D; Bühring M; Hess H
J Clin Pharmacol; 1986 Feb; 26(2):115-9. PubMed ID: 3512620
[TBL] [Abstract][Full Text] [Related]
13. Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research.
Support Care Cancer; 1994 May; 2(3):167-70. PubMed ID: 8032702
[TBL] [Abstract][Full Text] [Related]
14. Continuous i.v. infusion versus multiple bolus doses of metoclopramide for prevention of cisplatin-induced emesis.
Agostinucci WA; Gannon RH; Golub GR; Martin RS; Schauer PK; Dinonno EB
Clin Pharm; 1988 Jun; 7(6):454-7. PubMed ID: 3402181
[TBL] [Abstract][Full Text] [Related]
15. [Improved control of cisplatin-induced emesis with high-dose metoclopramide, dexamethasone and lorazepam].
Mau YK; Li YT; Tsui MS; Tu FC; Hsu KP
Zhonghua Yi Xue Za Zhi (Taipei); 1991 Feb; 47(2):116-20. PubMed ID: 1848133
[TBL] [Abstract][Full Text] [Related]
16. Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy.
Allen JC; Gralla R; Reilly L; Kellick M; Young C
J Clin Oncol; 1985 Aug; 3(8):1136-41. PubMed ID: 4020411
[TBL] [Abstract][Full Text] [Related]
17. A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
Sorbe BG; Högberg T; Glimelius B; Schmidt M; Wernstedt L; Hansen O; Sörensen BT; Räisänen I; van Oosterom AT; de Bruijn KM
Cancer; 1994 Jan; 73(2):445-54. PubMed ID: 8293412
[TBL] [Abstract][Full Text] [Related]
18. [Comparative study on the tolerance and efficacy of high doses of metoclopramide and clebopride in vomiting induced by cisplatin].
Martín M; Díaz-Rubio E
Med Clin (Barc); 1989 Jun; 93(2):50-3. PubMed ID: 2755259
[TBL] [Abstract][Full Text] [Related]
19. The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial.
O'Brien ME; Cullen MH; Woodroffe C; Kelly K; Burman C; Palmer K; Stuart NS; Blackledge GR; Sharpe J
Br J Cancer; 1989 Nov; 60(5):759-63. PubMed ID: 2679853
[TBL] [Abstract][Full Text] [Related]
20. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
